- nearly 400 pts have now been treated with ganetespib
- no bone marrow/neuro tox (they are seen w/ chemo)
- now inititating sites for docetaxel combo trial and will enroll first pt in next few weeks...early results by 1q12 (see below for more details)
- new HSP90 inhibitor combo trials 2011 w/ SOC in multiple myeloma, breast, prostate, AML, and w/ radiotherapy (2 unspecified tumor types added to SOC)- all IST or fndn supported to keep costs down
- p1 combo w/ docetaxel is fully enrolled. encouraged by safety profile, supportive of the large trial being initiated. more data this summer
- remain committed to completing one or more partnerships this year for one or more of 3 pgms. Favor regional deal gan and elesclomol, global deal for CRACM program
- $75m cash on hand after april offering
- net loss $11.4m
- cash suficient into 2h2012
- Q&A session:
- 1q12 data- interim results on only some fraction of first 240 pts (maybe 100 or more) safety and initial efficacy data
- 2 ongoing elesclomol trials. AML and ovarian
- plan NSCLC randomized eles trial 2h11 in 1st line pts w/ squamous morphology...completing additional biomarker work which will help ID pts most likely to benefit, then will proceed (1000x biomarkers related to MofA, some could be more significantly correlated than LDH)
- flexibility to change p3 ganetespib pgm to suit partner expectations? Yes
- ASCO: p2 NSCLC (oral, still not completely final, but close to 100 pt data), GIST study (oral poster discussion, about 30 pts), and some p1 data
RSS Feed
